High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an eastern cooperative oncology group protocol

Croig R. Nichols, Janet Andersen, Hillard M. Lazarus, Hugh Fisher, John Greer, Edward A. Stadtmauer, Patrick Loehrer, Donald L. Trump

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

Original languageEnglish (US)
Pages (from-to)558-563
Number of pages6
JournalJournal of Clinical Oncology
Volume10
Issue number4
StatePublished - 1992

Fingerprint

Autologous Transplantation
Germ Cell and Embryonal Neoplasms
Carboplatin
Etoposide
Bone Marrow Transplantation
Bone Marrow
Drug Therapy
Cisplatin
Kidney
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nichols, C. R., Andersen, J., Lazarus, H. M., Fisher, H., Greer, J., Stadtmauer, E. A., ... Trump, D. L. (1992). High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an eastern cooperative oncology group protocol. Journal of Clinical Oncology, 10(4), 558-563.

High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer : an eastern cooperative oncology group protocol. / Nichols, Croig R.; Andersen, Janet; Lazarus, Hillard M.; Fisher, Hugh; Greer, John; Stadtmauer, Edward A.; Loehrer, Patrick; Trump, Donald L.

In: Journal of Clinical Oncology, Vol. 10, No. 4, 1992, p. 558-563.

Research output: Contribution to journalArticle

Nichols, Croig R. ; Andersen, Janet ; Lazarus, Hillard M. ; Fisher, Hugh ; Greer, John ; Stadtmauer, Edward A. ; Loehrer, Patrick ; Trump, Donald L. / High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer : an eastern cooperative oncology group protocol. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 4. pp. 558-563.
@article{08d81d258aa448dfa138d7f7c8dc93a7,
title = "High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an eastern cooperative oncology group protocol",
abstract = "Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45{\%}) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13{\%}) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.",
author = "Nichols, {Croig R.} and Janet Andersen and Lazarus, {Hillard M.} and Hugh Fisher and John Greer and Stadtmauer, {Edward A.} and Patrick Loehrer and Trump, {Donald L.}",
year = "1992",
language = "English (US)",
volume = "10",
pages = "558--563",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer

T2 - an eastern cooperative oncology group protocol

AU - Nichols, Croig R.

AU - Andersen, Janet

AU - Lazarus, Hillard M.

AU - Fisher, Hugh

AU - Greer, John

AU - Stadtmauer, Edward A.

AU - Loehrer, Patrick

AU - Trump, Donald L.

PY - 1992

Y1 - 1992

N2 - Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

AB - Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026518779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026518779&partnerID=8YFLogxK

M3 - Article

C2 - 1312584

AN - SCOPUS:0026518779

VL - 10

SP - 558

EP - 563

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -